Discover 1,670 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,670
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
for
Advanced Solid Malignancies
Location: New Brunswick NJ, Richmond VA, Louisville KY,
Sponsor: Georgiamune Inc
Sex: All
Age: 18+
Code: NCT06028074
Phase 1, Phase 2, Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06297226
Phase 2, Recruiting
Addressing Genomic Disparities in Cancer Survivors
for
Hereditary Cancer, Genetic Testing
Location: New Brunswick NJ, Washington D.C. DC
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18 - 70+
Code: NCT06073626
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
for
Chronic Graft-versus-host-disease
Location: New Brunswick NJ, Philadelphia PA, Hackensack NJ,
Sponsor: Incyte Corporation
Sex: All
Age: 12+
Code: NCT06585774
Phase 3, Recruiting
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
for
Carcinoma, Hepatocellular, Liver Cell Carcinoma
Location: New Brunswick NJ, The Bronx NY
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18+
Code: NCT05366829
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Location: New Brunswick NJ, Philadelphia PA, Ney York NY,
Sponsor: Philogen S.p.A.
Sex: All
Age: 18+
Code: NCT03567889
Phase 3, Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
for
Metastatic HER2-positive Breast Cancer
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06435429
Phase 3, Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
for
Superficial Bladder Cancer,
Location: New Brunswick NJ, Philadelphia PA, Voorhees Township NJ,
Sponsor: enGene, Inc.
Sex: All
Age: 18+
Code: NCT04752722
Phase 1, Phase 2, Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
for
Non-Muscle Invasive Bladder Cancer
Location: New Brunswick NJ, Bala-Cynwyd PA, Los Alamitos CA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06319820
Phase 3, Recruiting
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
for
B-cell Non-Hodgkins Lymphoma (B-NHL)
Location: New Brunswick NJ, New York NY, Boston MA, Louisville KY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05685173
Phase 1, Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
for
Breast Neoplasms, Breast Cancer
Location: New Brunswick NJ, Fairfax VA, Boston MA, Kingston,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06686394
Phase 1, Phase 2, Recruiting
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Location: New Brunswick NJ, New York NY, Albany NY, Columbia SC,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 30
Code: NCT07437963
Phase 1, Phase 2, Recruiting
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Location: New Brunswick NJ, Toms River NJ, Long Branch NJ,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07504588
Phase 2, Recruiting
A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
for
Melanoma (Skin Cancer)
Location: New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18 - 70+
Code: NCT07830225
Recruiting
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)
for
Bladder Cancer
Location: New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18 - 70+
Code: NCT07762586
Phase 2, Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
for
Non-small Cell Lung Cancer (NSCLC)
Location: New Brunswick NJ, Edison NJ, Arlington VA,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07566052
Phase 3, Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: New Brunswick NJ, Somerville NJ, Philadelphia PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07391774
Phase 3, Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
for
Diffuse Large B-cell Lymphoma (DLBCL)
Location: New Brunswick NJ, Stony Brook NY, Baltimore MD,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06091865
Phase 3, Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
for
Lymphoma
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT07015242
Phase 2, Recruiting
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
for
Recurrent Glioblastoma, IDH-Wildtype,
Location: New Brunswick NJ, Livingston NJ, Newark NJ, New York NY,